Humanwell Healthcare and PuraCap to acquire Epic Pharma

China-based Humanwell Healthcare Group and PuraCap Pharmaceutical have entered into a definitive agreement to acquire 100% of privately-held US generic drugs marker Epic Pharma.

The acquisition, which involves a payment of $550 million, will further establish Humanwell and PuraCap in the US generics market and expand their existing commercial and manufacturing capabilities.

The acquisition of Epic will provide a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R&D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and powder formulations.